ProJect Pharmaceutics is proud to have contributed with its services, expertise and knowledge to develop a lyophilized i.v. injection formulation for one of its clients’ drug products which was approved by the U.S. Food and Drug Administration (FDA). Goal of the development was to move from an oral administration of the drug to an injectable one, for patients that are temporarily unable to take oral therapy thus enabling non-interruption of those patients’ therapy with the respective drug product. We congratulate our client by heart for this important achievement.
